In cART-treated patients, levels of pro-inflammatory cytokines are also associated with increased risk of CVD, independently from other CVD risk factors [84,85], and with infection-related and unrelated cancers, even after adjusting for demographics and CD4+ T cell counts [86]. This evidence concerns the gene CD4 and cancer.